Veracyte showed 15% revenue growth and 23% adjusted EBITDA growth in Q2 2026, with a 29.2% EBITDA margin and strong cash flow, operating without funded debt. The company is transitioning from a two-product genomic testing firm to a broader self-funded cancer diagnostic platform, supported by clinical evidence, specialist relationships, and reimbursement infrastructure. Upcoming product launches like Prosigna and TrueMRD offer significant growth potential, while core products Decipher and Afirma continue to drive growth and margin expansion. Veracyte’s valuation premium is supported by its operational leverage and durable competitive advantages based on evidence-based diagnostics.
Grayscale Investments has withdrawn its ETF registration applications for Cardano (ADA), Hedera (HBAR), and Polkadot (DOT) within minutes on August 7, 2026. These withdrawals follow earlier removal of related exchange-listing proposals and indicate a...
XRP is trading just above $1, struggling to break out due to a sharp decline in ETF inflows and ongoing uncertainty around U.S. crypto regulation. Institutional interest has waned, with ETF inflows dropping over 99% since May, as investors await clar...
Germany is considering supporting Bundesbank President Joachim Nagel as a candidate for the European Central Bank (ECB) presidency if Christine Lagarde resigns early. Nagel, known for his strong opposition to cryptocurrencies like Bitcoin and stablec...
DoorDash reported a 36% year-over-year revenue increase in Q2, reaching $4.45 billion and surpassing market expectations. The stock shows strong bullish technical signals, trading above its 30-week EMA and outperforming the S&P 500. Despite a lower v...
The US State Department has started the Freedom Tech Excellence Program (FTEP), partnering with private firms like Bitcoin Policy Institute and Palantir to enhance digital freedom globally. This initiative temporarily integrates private-sector specia...
